$EKSO yesterday announced preliminary Q4'24 topline financial results. Total Q4’24 revenue is estimated to be in the range of $5.0M to $5.1M, which is expected to be a Company record. Read more here:

$EKSO management will be participating at the 15th Annual Craig-Hallum Alpha Select Conference on Tuesday, Nov. 19 in NY. Learn more here:

Today, $EKSO reported Q3'24 financial results, highlighted by receipt of initial CMS reimbursement for Ekso Indego Personal, 33 EksoHealth devices sold, & the completion of a $5M underwritten offering. Read more here:

$EKSO will report its third quarter 2024 financial results after market close on Monday, October 28. Register and tune in for a live discussion of @EksoBionics financial results and recent business highlights:

We are excited to announce receipt of initial CMS reimbursement on our Ekso Indego Personal device. This represents a major milestone for individuals living with spinal cord injury. Read more in our press release here:

Today, $EKSO reported Q2'24 financial results, highlighted by record sales of $5M, a total of 37 EksoHealth devices sold, gross margin of 53% & initial Medicare claims for Ekso Indego Personal pending reimbursement. Read more about our results here:

We're excited to announce a research partnership with @ShepherdCenter, a renowned rehab hospital in Atlanta. Together, we're expanding the use of our EksoNR & Ekso Indego Personal devices across the continuum of care to enhance patient quality of life:

Exciting news! Our CEO, Scott Davis, has been featured in an interview with @WSTranscript discussing Ekso's mission of developing innovative exoskeletons for both rehabilitation & personal use to improve the lives of individuals with SCIs:

We are pleased to announce the appointment of Deborah Lafer Scher to Ekso's Board of Directors. As a distinguished leader, Ms. Scher brings extensive healthcare expertise and extensive experience with the VA to Ekso’s Board.

In case you missed it, @EksoBionics' Indego Personal was featured on Sunday on #HealthUncensored with @DrDrew on @FoxBusiness News.

Today, $EKSO reported Q1'24 financial results, highlighted by CMS’ determination of a final payment level of $91,031.93 for Medicare reimbursement of our Ekso Indego Personal, which took effect on April 1. Read more about our latest results here:

$EKSO will report its first quarter 2024 financial results after market close on Monday, April 29. Register and tune in for a live discussion of @EksoBionics financial results and recent business highlights:

@CMSGov finalized a reimbursement rate of $91,031.93 for Ekso Indego Personal which took effect April 1 2024. Eligible individuals with SCI covered under Medicare or Medicaid will be able to access our life-changing technology at a significantly lower cost

$EKSO's CEO Scott Davis was interviewed by @Aparmarbb for the latest @MedCityNews Pivot Podcast, where they dive into the neuromuscular energy, mobility, and rehabilitation benefits our revolutionary exoskeleton devices bring to patients. Tune in here:

Today, $EKSO reported fourth quarter and full year 2023 financial results highlighted by annual revenue of $18.3 million, up 42% Y/Y, and 151 EksoHealth devices sold, both company records. Read more about our results here:

Meet us at #AbilitiesExpoLA, March 15-17 at the LA Convention Center! 🌟 Experience the freedom of mobility with Ekso Indego Personal. Let's redefine independence together! See you there! #EksoIndegoPersonal

$EKSO will report its Q4 and FY'23 financial results after market close on Monday, March 4. Register and tune in for a live discussion on @EksoBionics financial results and recent business highlights:

$EKSO today announced the launch of GaitCoach™, its next generation gait therapy software for #EksoNR. Ekso believes GaitCoach will reduce training demands, increase utilization, & make the EksoNR more intuitive & easier to use for both patients & PTs.

$EKSO today announced preliminary Q4'23 top line financial results. Total Q4’23 revenue is estimated to be in the range of $4.7 million to $4.9 million, compared to total revenue of $3.6 million in Q4’22. Read more about today's announcement here:

The $EKSO Indego Personal has received CMS coding approval potentially expanding access to the SCI community at a substantially lower cost. HCPCS code K1007 is scheduled to take effect April 1 2024 with final payment determination expected in February 2024